I-SQUARED-CAPITAL
9.12.2020 17:02:08 CET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund II, has acquired and combined Infofabrica Holdings Pte Ltd and Cloud Kinetics Tech Pte Ltd, two Cloud migration services companies based in Singapore. The combined businesses are poised to become a leading Cloud migration and managed services provider in Southeast Asia and India, providing capability across all major public Cloud operators. These investments are part of a new Asian Digital Infrastructure platform and will enable I Squared Capital’s Digital Infrastructure companies to offer comprehensive Cloud-based solutions to their customers. The Cloud platform will have a growing pool of over 300 professionals with deep experience in Cloud infrastructure, data, analytics, application modernization and Cloud management and possess a broad range of Cloud certifications.
“The future of data and computing will be driven by the corporate adoption of hybrid Cloud solutions through an orchestrated mix of on-premises infrastructure, co-location and Cloud services. Offering seamless and efficient migration to the hybrid Cloud relieves a critical bottleneck to Cloud adoption, especially in the Asia-Pacific region. The combination of Infofabrica and Cloud Kinetics will result in a powerful Cloud migration solution provider for our clients,” said Gautam Bhandari, Managing Partner of I Squared Capital. “With these acquisitions, our global investments and commitments to the Digital Infrastructure sector are over $2.6 billion and growing.”
Cloud migration consists of the specialized capabilities and technologies, undertaken by certified experts, to enable businesses to move to and operate on the Cloud seamlessly. IDC predicts that Southeast Asia’s Cloud computing market will reach $40 billion by 2025, underscoring its importance in our daily lives. The platform is co-founded and being led by Haji Munshi, a technology executive who has held senior leadership positions at Google Cloud, Cisco, Hewlett Packard Enterprise and Dell, and Tameem Ebrahim, ex-Founding Partner of Quvat Capital and was an investment banker at Merrill Lynch and Deutsche Bank in Southeast Asia.
“The debate on the need for Cloud has ended after the experience of the Covid-19 pandemic,” said Haji Munshi, Group CEO of InfoFabrica and Cloud Kinetics. “Whether businesses are developing and testing their new applications, scaling their online e-commerce offerings, or running their core business workloads, this is possible only because of the stable, scalable solutions offered by the public Cloud. The demand for technical capability to migrate to Cloud has far outstripped supply in Asia-Pacific thus far and the combined company will be a market leader in Cloud migration services.”
“We are really pleased to be partnering with I Squared Capital, their expertise and breadth in Asia, along with existing large-scale investments in telecoms and data centers, will certainly accelerate and move us closer to our vision to be the top cloud migration and managed services provider in the region,” commented Abu Bakar Mohd Nor, Chairman of IFF. “The complementary capabilities of InfoFabrica and Cloud Kinetics is key and part of our strategy to be an end-to-end Cloud specialist and also simplify our clients’ Cloud migration journey.”
About Infofabrica Holdings (https://www.infofabrica.com/ ): Founded in 2013, InfoFabrica Holdings Pte Ltd has operations in Singapore, Indonesia, Vietnam and Malaysia. InfoFabrica is a certified Cloud partner of Amazon Web Services, Google Cloud, IBM Cloud.
About Cloud Kinetics (https://www.Cloud-kinetics.com/ ): Founded in 2012, Cloud Kinetics Tech Pte Ltd has operations in Singapore, Thailand, India and the United States. Cloud Kinetics is a certified Cloud partner of Microsoft Azure, Amazon Web Services and Google Cloud.
About I Squared Capital (http://www.isquaredcapital.com/ ): I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, digital infrastructure, transport and social infrastructure in the Americas, Europe and Asia. The firm has offices in Miami Hong Kong, London, New Delhi, New York, and Singapore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom